Hepatitis C treatment outcomes among patients treated in co-located primary care and addiction treatment settings.

Journal of Substance Abuse Treatment
Belle V NgoJudith I Tsui

Abstract

Persons with substance use disorders face major barriers to hepatitis C virus (HCV) treatment. Co-location of addiction and HCV treatment is appealing, yet there are limited data on outcomes using this model. This study evaluated HCV outcomes of patients treated with direct-acting antivirals (DAAs) by primary care providers in two sites of co-located addiction/HCV care. The study conducted a retrospective chart review for all patients receiving DAA treatment from 2016 to 2018 at 1) a hospital-based primary care clinic with an office-based buprenorphine program, and 2) a primary care clinic within an opioid treatment program (i.e. methadone clinic). The study classified patients into 3 groups according to treatment status: buprenorphine maintenance, methadone maintenance, or neither. Descriptive analyses compared patient demographics, clinical characteristics, adherence to monitoring and treatment, and the primary outcome of sustained virologic response at 12 weeks (SVR12), defined as an undetectable HCV viral load at least 12 weeks after completing treatment. This study included 50 patients who initiated DAA treatment. The majority of patients were unemployed (74.0%), did not smoke tobacco (54.0%), and had psychiatric comorbidi...Continue Reading

References

Sep 27, 2002·The New England Journal of Medicine·Michael W FriedJian Yu
May 17, 2006·Annals of Internal Medicine·Gregory L ArmstrongMiriam J Alter
May 27, 2006·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Richard K SterlingUNKNOWN APRICOT Clinical Investigators
Jan 16, 2010·Liver International : Official Journal of the International Association for the Study of the Liver·Beom Kyung KimKwang Hyub Han
Jun 3, 2011·The New England Journal of Medicine·Sanjeev AroraClifford Qualls
Feb 22, 2012·Annals of Internal Medicine·Kathleen N LyScott D Holmberg
Aug 2, 2013·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Philip Bruggmann, Alain H Litwin
Aug 13, 2014·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Anil G SuryaprasadScott D Holmberg
Mar 5, 2016·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Kathleen N LyScott D Holmberg
Nov 1, 2016·Annals of Internal Medicine·Gregory J DoreUNKNOWN C-EDGE CO-STAR Study Group
Oct 12, 2016·The American Journal of Gastroenterology·Stuart McPhersonQuentin M Anstee
Feb 27, 2017·Journal of Substance Abuse Treatment·Jenna L ButnerJeanette M Tetrault
Mar 21, 2017·Annals of Internal Medicine·Oluwaseun Falade-NwuliaMark S Sulkowski
Aug 16, 2017·The International Journal on Drug Policy·Brianna L NortonAlain H Litwin
Jan 9, 2018·Open Forum Infectious Diseases·Lauren F CollinsSusanna Naggie
May 19, 2018·Current HIV/AIDS Reports·Katherine M RichJudith Feinberg
May 26, 2018·Current HIV/AIDS Reports·Asher J SchranzWilliam C Miller
Mar 19, 2019·AIDS·Benjamin J OldfieldE Jennifer Edelman
Feb 6, 2020·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Sandra A Springer, Carlos Del Rio

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.